Secukinumab Causing Medication-Related Osteonecrosis of the Jaw, in a Patient Diagnosed with Psoriasis and Rheumatoid Arthritis

casuistics
Creative Commons License IconCreative Commons BY IconCreative Commons NC Icon
Thumbnail
File can be accessed.Get publication
Author
Hauer, LukášORCiD Profile - 0000-0001-6639-2690WoS Profile - T-1198-2017Scopus Profile - 55875669800
Moztarzadeh, OmidORCiD Profile - 0000-0002-4768-2382WoS Profile - KYQ-4453-2024Scopus Profile - 57190307831
Baghalipour, Nasimeh
Genčur, JiříORCiD Profile - 0000-0002-2842-4329WoS Profile - T-1228-2017Scopus Profile - 57193251645

Publication date
2024
Published in
Psoriasis
Volume / Issue
14 (23 September 2024)
ISBN / ISSN
ISSN: 2230-326X
ISBN / ISSN
eISSN: 2230-326X
Metadata
Show full item record
Collections
Abstract
The use of antiangiogenic and antiresorptive medications, particularly in patients with cancer or osteoporosis, can lead to osteonecrosis of the jaw following tooth extraction, trauma or arising spontaneously- A condition known as medication-related osteonecrosis of the jaw (MRONJ). In this article, we present a unique case of MRONJ in a patient with no history of antiresorptive or antiangiogenic drug use, who was instead taking the anti-interleukin 17-A (Secukinumab) medication for severe psoriasis. This association has not been previously reported in the literature.
Keywords
plaque psoriasis, anti-interleukin 17-A, immunomodulator, interleukins inhibitors, MRONJ,
Permanent link
https://hdl.handle.net/20.500.14178/2677
Show publication in other systems
WOS:001319532000001
PUBMED:39347517
License

Full text of this result is licensed under: Creative Commons Uveďte původ-Neužívejte dílo komerčně 3.0 Unported

Show license terms